Regulus Therapeutics Inc

Regulus Therapeutics Inc Stock Forecast & Price Prediction

Live Regulus Therapeutics Inc Stock (RGLS) Price
$1.62

6

Ratings

  • Buy 1
  • Hold 5
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.62

P/E Ratio

-1.03

Volume Traded Today

$296,701

Dividend

Dividends not available for RGLS

52 Week High/low

3.79/1.08

Regulus Therapeutics Inc Market Cap

$104.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $RGLS ๐Ÿ›‘

Before you buy RGLS you'll want to see this list of ten stocks that have huge potential. Want to see if RGLS made the cut? Enter your email below

RGLS Summary

From what 6 stock analysts predict, the share price for Regulus Therapeutics Inc (RGLS) might increase by 537.65% in the next year. This is based on a 12-month average estimation for RGLS. Price targets go from $3 to $28. The majority of stock analysts believe RGLS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

RGLS Analyst Ratings

Regulus Therapeutics Inc has a total of 6 Wall St Analyst ratings. There are 1 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Regulus Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

RGLS stock forecast by analyst

These are the latest 20 analyst ratings of RGLS.

Analyst/Firm

Rating

Price Target

Change

Date

Andreas Argyrides
Oppenheimer

Outperform

$7

Reiterates

Aug 14, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Aug 9, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Reiterates

Jul 16, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$10

Maintains

Jun 25, 2024
Whitney Ijem
Canaccord Genuity

Buy

$28

Maintains

Jun 25, 2024
Catherine Novack
Jones Trading

Buy

$8

Initiates

May 31, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

May 10, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

May 6, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Mar 25, 2024
Whitney Ijem
Canaccord Genuity

Buy

$11

Maintains

Mar 19, 2024
Joseph Schwartz
Leerink Partners

Outperform

$6

Initiates

Mar 18, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Mar 18, 2024
Jim Birchenough
Wells Fargo

Equal-Weight

$3

Maintains

Mar 13, 2024
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Sep 21, 2023
Whitney Ijem
Canaccord Genuity

Buy

$12

Maintains

Sep 21, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Sep 19, 2023

HC Wainwright & Co.

Buy


Reiterates

Aug 10, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Jun 28, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

Jun 21, 2023
Raghuram Selvaraju
HC Wainwright & Co.

Buy

$9

Reiterates

May 15, 2023

RGLS Company Information

  • Company Type: Clinical-stage biopharmaceutical company
  • Focus: Discovery and development of drugs targeting microRNAs
  • Primary Product Candidate: RGLS8429 - an anti-miR oligonucleotide targeting miR-17
  • Current Development Stage: Phase 1b clinical trial for autosomal dominant polycystic kidney disease
  • Pipelines: Developing preclinical drug products for target organ-selective delivery strategies
  • Incorporation Year: 2007
  • Headquarters: San Diego, California
RGLS
Regulus Therapeutics Inc (RGLS)

When did it IPO

2012

Staff Count

31

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Joseph P. Hagan M.B.A.

Market Cap

$104.7M

Regulus Therapeutics Inc (RGLS) Financial Data

In 2023, RGLS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RGLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$10.0M

Revenue From 2021

$0

-100.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -31.7%
  • Return on equity TTM -53.5%
  • Profit Margin 0.0%
  • Book Value Per Share 1.50%
  • Market capitalisation $104.7M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-1.20

Regulus Therapeutics Inc (RGLS) Latest News

No news data available.

...

RGLS Frequently asked questions

The highest forecasted price for RGLS is $28 from Whitney Ijem at Canaccord Genuity.

The lowest forecasted price for RGLS is $3 from Jim Birchenough from Wells Fargo

The RGLS analyst ratings consensus are 1 buy ratings, 5 hold ratings, and 0 sell ratings.